Disclosed herein are new, useful, and non-obvious means of stimulating therapeutic angiogenesis, or conditions favorable for stimulation of therapeutic angiogenesis utilizing T regulatory cells. One disclosed method includes administering a population of T regulatory cells into an area of hypoxia to stimulate angiogenesis. T regulatory cells are generated and expanded by culture with mesenchymal stem cells, with either population or both populations together administered into the hypoxic area.

Compositions and methods are provided for the culture of mammalian distal lung organoids that robustly preserve and propagate distal lung alveoli and bronchioles en bloc with infiltrating endogenous immune cells and mesenchyme as a cohesive unit without artificial reconstitution, allowing analysis of the dynamics of tissue-level inflammation upon respiratory infection.

Disclosed herein are a cell laminate including an epidermal layer in which specific gene-deficient epidermal keratinocytes are laminated; a method for producing a cell laminate, including a step of culturing specific gene-deficient epidermal keratinocytes by air-liquid interface culture; and applications thereof.

Disclosed herein are methods and compositions for providing mixtures of FGF2 isoforms that are biologically active. The biological activities include, but are not limited to, stimulation of proliferation of neural precursor cells, stimulation of proliferation of endothelial cells, stimulation of development of neural precursor cells, and stimulation of development of astrocytes.

Provided are a method for producing a cell tissue, including a culturing step of culturing cells capable of serving as a feeder inside opening pores and communicating pores of a porous film having a plurality of the opening pores provided on a surface thereof and the communicating pores communicating mutually adjacent opening pores with one another; and a porous film including a plurality of opening pores provided on a surface thereof and communicating pores communicating mutually adjacent opening pores with one another.

A device for culturing a liver tissue has a culture chamber to which at least two flow channels, which are at least for introducing and discharging a culture medium, are connected. A gel which serves as a cell scaffold material is housed in the culture chamber. A co-culture system containing an endothelial cell-derived cell, a hepatocyte-derived cell and a mesenchymal cell is co-cultured on the gel in such a way that the co-culture system has a tubular structure.

[Problem] To provide a method for producing human corneal epithelial sheet, wherein the human corneal epithelial-derived cells obtained by culturing human corneal epithelial cells are cultured on an amnion substrate. [Solution] A method for culturing human corneal epithelial cells using mesenchymal stem cells as the feeder cells; and a method for culturing human corneal epithelial cells using a medium containing a ROCK inhibitor, a phosphodiesterase inhibitor, a MAP kinase inhibitor and a TGF- receptor inhibitor in various combinations.

Methods, kits and compositions for generating cancer stem cells are provided.

Embodiments of the present disclosure concern systems, methods, and compositions for both in vitro and in vivo models of metastases, such as bone metastases. In specific embodiments, there is a system comprising a source of bone cells, such as osteoblasts, and a source of cancer cells, wherein the bone cells and cancer cells are configured in a chamber or on a chick chorioallantoic membrane such that interaction between the cells is determined. In specific embodiments, the bone cells are comprised in an organoid comprising both mesenchymal stem cells and osteoblasts (although a naturally derived bone scaffold may be employed), and the cancer cells are comprised in an organoid comprising mesenchymal stem cells and the cancer cells.

A method for modifying gene expression of diseased cells in a patient including preparing an extract of diseased cells, forming a plurality of conditioned stem cells by treating a plurality of normal stem cells with a solution of the extract of the diseased cells with a volume ratio between 10.sup.15 volume/volume (v/v) and 10.sup.3 v/v (volume of the extract of the diseased cells/volume of a culture medium), forming a conditioned stem cell-derived extract, and forming a plurality of healthy cells by treating the diseased cells with the conditioned stem cell-derived extract.